Search

Displaying results 3931 - 3940 of 7186 in total
  1. Drug

    1alpha,24S-Dihydroxyvitamin D2

    go.drugbank.com/drugs/DB06117
    Experimental

    LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol. … Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.

  2. Drug

    PRO-542

    go.drugbank.com/drugs/DB05793
    Investigational

    PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells.

  3. Drug

    Melaleuca alternifolia leaf

    go.drugbank.com/drugs/DB14372
    Investigational

    Melaleuca alternifolia leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Synonyms: Narrow-leaved Ti-tree LeafMixtures: SEED Teatree and Lime Vegan No-sebum Cool Anti HairlossShampoo, Pimplepatch By Glam Up
  4. Drug

    ILY101

    go.drugbank.com/drugs/DB05059
    Investigational

    ILY101 is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs. … ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract.

  5. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    [L63350,L63932] The combination is aimed at multidrug-resistant Gram-negative infections, a group for which treatment options are limited and where resistance to carbapenems has narrowed the available … [L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated

  6. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. … It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.

  7. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    [L52270] Revakinagene taroretcel delivers CNTF to the retina to lower the extent of neuroregeneration. … Revakinagene taroretcel is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF).

  8. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [L44537] Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain [A253947,A253952] with high selectivity to Aβ protofibrils. … [A253947,A253957] In clinical trials, it significantly reduced brain Aβ plaques compared to placebo.

  9. Drug

    Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15731
    Investigational

    ORBCEL-C™ is the trade name of a product composed of highly purified stromal cells derived from the human umbilical cord. … The isolated cells are expanded in culture and are able to be used allogenically -- meaning that one donor’s cells can be given to other unrelated patients.

  10. Drug

    Lercanidipine

    go.drugbank.com/drugs/DB00528
    ApprovedInvestigationalWithdrawn

    Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.